Inhibition of STAT6 during vaccination with formalin-inactivated RSV prevents induction of Th2-cell-biased airway disease

European Journal of Immunology

Volumn 44, Issue 8, 2014, Pages 2349-2359

  Srinivasa, Bharat T ^a   Fixman, Elizabeth D ^b   Ward, Brian J ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Formalin inactivated RSV vaccine; Respiratory syncytial virus; STAT6; STAT6 inhibitory peptide; Vaccine enhanced disease

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CELL PENETRATING PEPTIDE; FORMALDEHYDE; FORMALIN INACTIVATED RESPIRATORY SYNCYTIAL VIRUS VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INACTIVATED VIRUS VACCINE; PROTEIN INHIBITOR; RESPIRATORY SYNCYTIAL VIRUS VACCINE; STAT6 INHIBITORY PEPTIDE; STAT6 PROTEIN; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG POTENTIATION; EARLY INTERVENTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INTRACELLULAR SIGNALING; LEUKOCYTE DIFFERENTIAL COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE; TH2 CELL; VACCINATION;

FORMALIN-INACTIVATED RSV VACCINE; RESPIRATORY SYNCYTIAL VIRUS; STAT6; STAT6-INHIBITORY PEPTIDE; VACCINE-ENHANCED DISEASE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOKINES; EOSINOPHILS; FORMALDEHYDE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; INTERFERON-GAMMA; LUNG; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR; TH2 CELLS; VACCINES, INACTIVATED;

EID: 84906088893     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201344206     Document Type: Article

References (40)

1. Hall, C. B., The burgeoning burden of respiratory syncytial virus among children. Infect. Disord. Drug Targets 2012. 12: 92-97.
2. Nair, H., Nokes, D. J., Gessner, B. D., Dherani, M., Madhi, S. A., Singleton, R. J., O'Brien, K. L. et al., Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010. 375: 1545-1555.
3. Szabo, S. M., Levy, A. R., Gooch, K. L., Bradt, P., Wijaya, H. and Mitchell, I., Elevated risk of asthma after hospitalization for respiratory syncytial virus infection in infancy. Paediatr. Respir. Rev. 2013. 13(Suppl 2): S9-S15.
4. Falsey, A. R., Hennessey, P. A., Formica, M. A., Cox, C. and Walsh, E. E., Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 2005. 352: 1749-1759.
5. Mohapatra, S. S. and Boyapalle, S., Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma. Clin. Microbiol. Rev. 2008. 21: 495-504.
6. Lee F. E.-H., Walsh, E. E., Falsey, A. R., Lumb, M. E., Okam, N. V., Liu, N., Divekar, A. A. et al., Human infant respiratory syncytial virus (RSV)-specific type 1 and 2 cytokine responses ex vivo during primary RSV infection. J. Infect. Dis. 2007. 195: 1779-1788.
7. Kim, C. K., Kim, S. W., Park, C. S., Kim, B. I., Kang, H. and Koh, Y. Y., Bronchoalveolar lavage cytokine profiles in acute asthma and acute bronchiolitis. J. Allergy Clin. Immunol. 2003. 112: 64-71.
8. Puthothu, B., Krueger, M., Forster, J. and Heinzmann, A., Association between severe respiratory syncytial virus infection and IL13/IL4 haplotypes. J. Infect. Dis. 2006. 193: 438-441.
9. Cormier, S. A., You, D. and Honnegowda, S., The use of a neonatal mouse model to study respiratory syncytial virus infections. Expert Rev. Anti. Infect. Ther. 2010. 8: 1371-1380.
10. Goenka, S. and Kaplan, M. H., Transcriptional regulation by STAT6. Immunol. Res. 2011. 50: 87-96.
11. Ho, A., Schwarze, S. R., Mermelstein, S. J., Waksman, G. and Dowdy, S. F., Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res. 2001. 61: 474-477.
12. McCusker, C. T., Wang, Y., Shan, J., Kinyanjui, M. W., Villeneuve, A., Michael, H. and Fixman, E. D., Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominant-negative STAT-6 peptide. J. Immunol. 2007. 179: 2556-2564.
13. Wang, Y., Li, Y., Shan, J., Fixman, E. and McCusker, C., Effective treatment of experimental ragweed-induced asthma with STAT-6-IP, a topically delivered cell-penetrating peptide. Clin. Exp. Allergy 2011. 41: 1622-1630.
14. Polack, F. P., Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatr. Res. 2007. 62: 111-115.
15. Belshe, R. B., Van Voris, L. P. and Mufson, M. A., Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J. Infect. Dis. 1982. 145: 311-319.
16. Fulginiti, V. A., Eller, J. J., Sieber, O. F., Joyner, J. W., Minamitani, M. and Meiklejohn, G., Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines. an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 1969. 89: 435-448.
17. Kapikian, A. Z., Mitchell, R. H., Chanock, R. M., Shvedoff, R. A. and Stewart, C. E., An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 1969. 89: 405-421.
18. Kim, H. W., Canchola, J. G., Brandt, C. D., Pyles, G., Chanock, R. M., Jensen, K. and Parrott, R. H., Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 1969. 89: 422-434.
19. Graham, B. S., Henderson, G. S., Tang, Y. W., Lu, X., Neuzil, K. M. and Colley, D. G., Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 1993. 151: 2032-2040.
20. Waris, M. E., Tsou, C., Erdman, D. D., Zaki, S. R. and Anderson, L. J., Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 1996. 70: 2852-2860.
21. Castilow, E. M., Olson, M. R. and Varga, S. M., Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol. Res. 2007. 39: 225-239.
22. Connors, M., Giese, N. A., Kulkarni, A. B., Firestone, C. Y., Morse, H. C., 3rd and Murphy, B. R., Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 1994. 68: 5321-5325.
23. Connors, M., Kulkarni, A. B., Firestone, C. Y., Holmes, K. L., Morse, H. C., 3rd, Sotnikov, A. V. and Murphy, B. R., Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4 + T cells. J. Virol. 1992. 66: 7444-7451.
24. Cyr, S. L., Jones, T., Stoica-Popescu, I., Brewer, A., Chabot, S., Lussier, M., Burt, D. et al., Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology. Vaccine 2007. 25: 5378-5389.
25. Olson, M. R., Hartwig, S. M. and Varga, S. M., The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. J. Immunol. 2008. 181: 7958-7968.
26. Hall, C. B., Weinberg, G. A., Iwane, M. K., Blumkin, A. K., Edwards, K. M., Staat, M. A., Auinger, P. et al., The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 2009. 360: 588-598.
27. Lee, N., Lui, G. C. Y., Wong, K. T., Li, T. C. M., Tse, E. C. M., Chan, J. Y. C., Yu, J. et al., High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin. Infect. Dis. 2013. 57: 1069-1077.
28. Openshaw, P. J. M. and Tregoning, J. S., Immune responses and disease enhancement during respiratory syncytial virus infection. Clin. Microbiol. Rev. 2005. 18: 541-555.
29. Tang, Y. W. and Graham, B. S., Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J. Clin. Invest. 1994. 94: 1953-1958.
30. Stevens, W. W., Sun, J., Castillo, J. P. and Braciale, T. J., Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease. Viral Immunol. 2009. 22: 243-251.
31. Castilow, E. M., Meyerholz, D. K. and Varga, S. M., IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease. J. Immunol. 2008. 180: 2376-2384.
32. Castilow, E. M., Legge, K. L. and Varga, S. M., Cutting edge: eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease. J. Immunol. 2008. 181: 6692-6696.
33. Olson, M. R. and Varga, S. M., CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J. Immunol. 2007. 179: 5415-5424.
34. Srikiatkhachorn, A. and Braciale, T. J., Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med. 1997. 186: 421-432.
35. Mikita, T., Daniel, C., Wu, P. and Schindler, U., Mutational analysis of the STAT6 SH2 domain. J. Biol. Chem. 1998. 273: 17634-17642.
36. Loebbermann, J., Durant, L., Thornton, H., Johansson, C. and Openshaw, P. J., Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells. Proc. Natl. Acad. Sci. USA 2013. 110: 2987-2992.
37. Reed, L. and Muench, H., A simple method of estimating fifty percent endpoints. Am. J. Hygiene 1938. 27: 493-497.
38. Prince, G. A., Curtis, S. J., Yim, K. C. and Porter, D. D., Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J. Gen. Virol. 2001. 82: 2881-2888.
39. Graham, B. S., Bunton, L. A., Wright, P. F. and Karzon, D. T., Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J. Clin. Invest. 1991. 88: 1026-1033.
40. Ponnuraj, E. M., Hayward, A. R., Raj, A., Wilson, H. and Simoes, E. A., Increased replication of respiratory syncytial virus (RSV) in pulmonary infiltrates is associated with enhanced histopathological disease in bonnet monkeys (Macaca radiata) pre-immunized with a formalin-inactivated RSV vaccine. J. Gen. Virol. 2001. 82: 2663-2674.